CRDA: Glycemic Outcomes (2023)

CRDA: Glycemic Outcomes (2023)

• Intervention
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on fasting blood glucose?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on fasting blood glucose in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Low (C)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on fasting blood glucose?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
      • Ryan M, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond P, Johnson N, Wilson A. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of Hepatology 2013; 59:138-143
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023
     
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on hemoglobin A1c?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on HbA1c in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Low (C)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on hemoglobin A1c?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023